Orexo US Blog Contact EN About Us Key Therapeutic Areas Pharmaceuticals Digital Therapies Sustainability Investors Media OREXO ABOUT US BOARD OF DIRECTORS & MANAGEMENT Board of Directors & Management Board of Directors Management James Noble Chairman of the Board of Directors Born 1959. Chairman of the Board of Directors since 2020. M.A. from the University of Oxford. Other appointments: Board member of Adaptimmune since 2008. Board member and Deputy Chairman of GW Pharmaceuticals since 2007. Previous appointments: Brings more than 30 years of industry experience from both the private and the public sector, which includes: being co-founder of Adaptimmune and founder and CEO of Immunocore. Has also been Chairman and CEO of Avidex, which was aquired by Medigene. James has held several positions as board member at companies including, among others, Medigene, PowderJect Pharmaceuticals and CuraGen Corporation. Holds 9,500 shares, and bonds of a nominal value of SEK 2,500,000.1 Staffan Lindstrand Board member Born 1962. Board member since 2002. M.Sc. in Engineering. Other appointments: Partner of HealthCap since 1997, Board member of HealthCap AB, PulmonX Inc., Doctrin AB and The Swedish Association of Exchange-listed Companies. Previous appointments: Ten years in investment banking. Holds 881 shares.1 Charlotte Hansson Board member Born 1969. Board member since 2020. MSc. in Business Administration from Handelshögskolan at the University of Gothenburg. Other appointments: CFO at Systembolaget AB, since 2015. Previous appointments: Has been Group CFO & Executive VP at Cision AB. Charlotte has also been Group CFO at Addici AB. Before this she had an extensive career within business controlling, with many year at, for instance, Modern Times Group (MTG). Holds 2,500 shares.1 Henrik Kjaer Hansen Board member Born 1976. Board member since 2018. BSc. in Business Administration and a MSc. in Applied Economic and Finance at Copenhagen Business School. Other appointments: Senior Director, Principal Investments, Novo Holdings A/S. Board member of Xellia Pharmaceutical. Previous appointments: Prior to joining Novo Holdings A/S, Kjaer Hansen was employed as a Senior Vice President in Moelis & Co. in London, focusing on healthcare M&A transactions. Other previous employments include Deutsche Bank and ABN AMRO, all in London. Does not hold any shares in Orexo.1 David Colpman Board member Born 1961. Board member since 2015. B.Sc. Pharmacy. Other appointments: Director of Colpman Consulting Ltd since 2014. Member of the Royal Pharmaceutical Society. Board member of HRA Pharma and Forendo Pharma Ltd. Previous appointments: Former Head of Global Business Development 2012–2014, Senior Vice President of Business Development at Shire plc 1999–2012. Various business development and commercial positions at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals. Holds 4,379 shares.1 Kirsten Detrick Board member Boarn 1965. Board member since April 2016. MBA. Other appointments: Managing Director at Takeda Austria GmbH and Takeda Osteuropa Holding GmbH since July, 2016. Previous appointments: Vice President Global Marketing, Therapeutic Area Commercial Lead – GI at Takeda Pharmaceuticals, Executive Director positions within US as well as Global Marketing and Commercialization at Amgen Inc. 2004–2013, Various marketing and commercial positions at Bristol-Myers Squibb 1991–2004. Former member of the Board of Southern California Biomedical Council and member of Healthcare Businesswomen’s Association. Holds 1,500 American Depository Receipts, listed in USD.1 Mary Pat Christie Board member Born 1963. Board member since 2019. MBA. Other appointments: Board member of Hackensack Meridian Health’s Carrier Clinic and Restaurant Technologies. Previous appointments: Managing Director at Angelo Gordon & Co., where she focused on business development of new fund strategies and new strategic alliances. Prior to that Mrs Christie worked at Cantor Fitzgerald as an Institutional Salesperson and was an original partner at the Seaport Group. Mary Pat was also the founder of Mendham Capital Management. Her career also includes high level roles at JP Morgan, Donaldson, Lufkin & Jenrette, and Fleet Bank. Holds 1,150 American Depository Receipts, listed in USD.1 Fred George Wilkinson Board member Born 1956. Board member since 2019 MBA., B.Sc. Pharmacy Other appointments: Fred currently serves as board member of Alter Pharma Group. Previous appointments: Has served as President and Chief Executive Officer of Impax Laboratories, Inc. from 2014 until December 2016. Prior to that, Fred held the position of President of the Specialty business at Watson Pharmaceuticals, Inc. (currently Allergan) from 2009 through 2014. Other previous employments include among others President of Duramed Pharmaceuticals, Inc., Chief Executive Officer of Columbia Laboratories, and multiple positions at Sandoz Pharmaceutical Corp. Fred has previously served as board member of Impax Laboratories, Inc., Columbia Laboratories, Inc., Moksha8 Pharmaceuticals, Inc. and Somerset Pharmaceuticals, Inc. Holds 2,100 American Depository Receipts, listed in USD.1 1 As of June 30, 2021 Thanks and welcome back! ©2021 Orexo AB (publ.) – All rights reserved Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy